Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
43,692,643
-
Total 13F shares
-
28,863,580
-
Share change
-
-1,089,597
-
Total reported value
-
$107,955,539
-
Put/Call ratio
-
6%
-
Price per share
-
$3.74
-
Number of holders
-
87
-
Value change
-
-$6,770,447
-
Number of buys
-
48
-
Number of sells
-
41
Institutional Holders of Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX) as of Q4 2024
As of 31 Dec 2024,
Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX) was held by
87 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
28,863,580 shares.
The largest 10 holders included
Vida Ventures Advisors, LLC, GILEAD SCIENCES, INC., Bain Capital Life Sciences Investors, LLC, JPMORGAN CHASE & CO, Novo Holdings A/S, BlackRock, Inc., VANGUARD GROUP INC, Insight Holdings Group, LLC, MILLENNIUM MANAGEMENT LLC, and FRANKLIN RESOURCES INC.
This page lists
87
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.